TBPH
Theravance Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · KY
$17.03
+0.00%Price chart
Aug 26Aug 31Sep 3Sep 9Sep 14Sep 17Sep 22Sep 25
Key dataSep 25, 2026
Open$17.03
From 52W high−17.89%
Volume0.00
Market cap$884.18M
P/E (TTM)16.0x
P/S (TTM)8.5x
Div yield—
Key dataSep 25, 2026
Open
$17.03
From 52W high
−17.89%
Volume
0.00
Market cap
$884.18M
ValuationView details →
P/E (Fwd)
5.9x
EV/EBITDA
7.8x
P/E (TTM)
16.0x
RSI (14)
53.2
MomentumView details →
1D Return
+0.00%
YTD Return
−8.98%
SummaryUpdated Jun 1, 2026
Theravance Biopharma, Inc. (NASDAQ:TBPH) is a biopharmaceutical company founded in 2013 and incorporated in the Cayman Islands with operations based in George Town. The company emerged as a spinoff focused on developing and commercializing respiratory medicines and other therapeutic treatments. Theravance operates primarily in the United States, Europe, and Asia, with a concentrated focus on respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), and rare neurological conditions. The company has transitioned from a broad research-focused organization to a more streamlined entity concentrating on its core commercial asset and late-stage pipeline candidates.
Similar companies
Latest newsMore news →
Vir Biotechnology, Inc. appointed Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026.19d agoZymeworks Inc. completed its previously announced acquisition of Theravance Biopharma, which is now part of Zymeworks.26d agoTheravance Biopharma is facing several lawsuits seeking to block its acquisition by Zymeworks.40d ago